FDA Inspection 1244025 — Christopher Harle, M.B.
The FDA completed an inspection of Christopher Harle, M.B. on Jun 14, 2024 in London. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 14, 2024
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- London (Canada)
Additional Details
Clinical Investigator (CI)